Kevin Fowler, kidney transplant recipient and Principal of The Voice of the Patient, discusses his role as a consultant to Memo Therapeutics, contributing to site engagement and enrollment for the Phase II potravitug trial, as well as forming and executing a patient advisory board. In this interview, Kevin shares his perspective on the encouraging trial results, highlighting potravitug’s effectiveness demonstrated through kidney biopsy data and its well-tolerated safety profile. As someone who has lived with a kidney transplant since 2004 and experienced BK polyomavirus (BKPyV) firsthand, he emphasizes the critical unmet need for approved BKPyV treatments, noting that current standard of care of reducing immunosuppressive medications carries significant risks, including acute rejection of the transplant.
